University of North Dakota

UND Scholarly Commons
Nursing Capstones

Department of Nursing

3-8-2016

Incidence and Management of Polypharmacy
Zillah Mulubisha

Follow this and additional works at: https://commons.und.edu/nurs-capstones
Recommended Citation
Mulubisha, Zillah, "Incidence and Management of Polypharmacy" (2016). Nursing Capstones. 16.
https://commons.und.edu/nurs-capstones/16

This Independent Study is brought to you for free and open access by the Department of Nursing at UND Scholarly Commons. It has been accepted for
inclusion in Nursing Capstones by an authorized administrator of UND Scholarly Commons. For more information, please contact
zeineb.yousif@library.und.edu.

Running header: Incidence and Management of Polypharmacy
1

Incidence and Management of Polypharmacy
Independent Study
Zillah Mulubisha
University Of North Dakota
4/08/15

Incidence and Management of Polypharmacy
2

Title: Incidence and management of polypharmacy

Degree: Masters in Nursing

In presenting this independent study in partial fulfillment of the requirements for a graduate
degree from the University of North Dakota, I agree that the College of nursing of this
University shall make it freely available for inspection. I further agree that permission for
extensive copying or electronic access for scholarly purposes may be granted b the professor
who supervised my independent study work or, in her absence, by the chairperson of the
department or the dean of the Graduate School. I understand that any copying or publication or
other use of this independent study or part thereof for financial gain shall not be allowed without
my written permission. It is also understood that due recognition shall be given to me and to the
University of North Dakota in any scholarly use which may be made of any material in my
independent study.

Signature______________

Date__________________

Incidence and Management of Polypharmacy
3

Abstract
There is a growing concern related to poly pharmacy in various generations with a special
interest in elderly. The geriatric population is at high risk of having various chronic illness and in
turn uses multiple medications for their chronic illness. When talking about polypharmacy, what
would one expect to see? What are the incidences related to polypharmacy and how can that be
managed? Polypharmacy is described as having prescriptions of multiple drugs. Other definitions
state polypharmacy as the use of multiple medications. No article seems to define the number of
drugs that can be considered as multiple. Other articles have number ranges from five to twenty
or more medications. Poly pharmacy is hence addressed as a general use of various medications
both over the counter and prescription. The goal of this paper is to make our society aware of the
need to review and reconcile patients’ medications in order to reduce the negative incidence and
management of polypharmacy.
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Background
"I woke up this morning feeling shakily and my heart pounding. It felt as though I was
going to die and I was scared to call ambulance. I thought I should just come in and see you."
This was a statement told to a primary care provider from a geriatric patient during a routine
follow up visit. Upon assessment and review of the patient’s medications, the provider noted that
the patient had been taking the wrong time and amount of his Flomax. He was taking at least
seven medications and most of them were to be taken two to three times a day. He had
understood that he should take the capsule three times a day. On his medication list he had
omeprazole and Flomax that were both capsules. According to his previous visit, his
understanding was to take the capsules three times a day and since he picked both bottle after
that visit he was not able to differentiate the two and took the Flomax versus the omeprazole
three times a day.
Another example was a 78-year-old female leaving independently in an assisted living
managing her medications independently with at least six comorbidities including but not limited
to diabetes, chronic kidney failure, and hypertension. She had been hospitalized four times
within the past month with hypoglycemia episodes. Prior to all her admissions she had been
managing her diabetes with metformin and maintained blood glucose levels with 100 – 250
mg/dl. Her hemoglobin A1C was 7.5. Upon further assessment the provider noted that she had
been taking her short-acting insulin three times a day and her blood glucose was very low during
the night. She was taking her last snack at 7pm and going to bed per her previous routine. She
had maintained using the short-acting per teaching that she had received at the hospital three
times a day, not considering the carbohydrates she was taking. Review of her hospital records
indicate that she was eating at least six carbohydrates with every meal while at the hospital. Her
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metformin had been discontinued and she was to start on both short- and long-acting insulin. Her
blood glucose was managed well due to a structured setting and her meals being monitored.
While at the assisted living she was making her own choices on the meal she was taking. She
was still taking metformin per her old records and added the insulin to her list. That played a
huge impact on her blood glucose since she had been scheduled to take six units of Novolog
three times a day and taking metformin twice day. This caused the frequent hypoglycemic
episodes because most days she was taking at least three or less carbohydrates, then snacking in
between per her old routine.
Polypharmacy may have indications as above due to poor understanding of one’s
medication management. The need for providers to take time and review patients’ medications
may be relevant in reducing incidence and managing polypharmacy. Ferner & Aronson (2006)
state that in an ideal situation prescribing information should have the potential side effects of
every drug, whereby one should be able to know probability of harm in relation to the dose, time
and factors that alter one’s susceptibility. Communicating therefore can enable patients’
awareness on what kinds of medications they are taking and a better understanding of potential
side effects.
Research has shown that the incidence of polypharmacy occurs more with older adults
especially in the geriatric populations who have a higher rate of chronic comorbidities. This
increases their chance of having multiple prescriptions for various disease processes. Steinman,
Lund, Miao, Boscardin, & Kaboli, (2011) completed a study that showed the adverse drug
effects to geriatric patients, and how drug interactions increased functional impairments such as
falls, and cognitive status. This study also showed the probability of adverse drug interactions
hinder the older adults or geriatrics from functioning at an optimal level. For instance using
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antihypertensive can increase risks of orthostatic blood pressure when patients have impaired
vascular tone, they are unable to compensate the physiological changes caused by the
medications. This would then increase the rate of falls in this population and may lead to another
comorbidity like fracture or limited mobility due to pain.
Managing polypharmacy may be difficult when patients have or use various providers
that need to be in direct communication with all changes on medication prescription. This can be
an issue with patients that utilize specialty services on multiple concerns. An example is a patient
that has an oncologist, hematologist, cardiology, and a primary care provider. If a clear line of
treatment is not indicated, the patient would receive medications or procedures that can be
repeated in another clinic. Steinman, Lund, Miao, Boscardin, & Kaboli, (2011) explains that
ongoing review of drug interactions is necessary; stating that adverse drug reactions can be noted
at early stages of initiating a new medication. Therefore caution is needed when starting new
medications, with a recommendation of initiating one drug at a time or discontinuing one drug at
time. It would also benefit patients to have a follow up visit with their primary care providers
less than seven days after discharge to review their recent admission and current plan being
maintained after discharge.
Case Report
Chief Complaint: 87 year old female at the clinic for a follow up visit after a recent admission
with urinary tract infection and fatigue for 3 days. She is also feeling dizzy.
HPI:
Ms. E.M is at the clinic today for a follow up visit after a recent discharge. She reports feeling
much better and denies having dysuria, frequency, urgency or lower back pain. She reports that
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she has been taking her antibiotic and has at least 3 doses left to finish her dosage. She denies
having a fever or chills and denies pain. She is c/o of dizziness and fatigue that is ongoing, she
states that the dizziness is more in the morning when she awaken or move from a sitting to
standing. She denies having vertigo and states that the dizziness resolves when she takes time or
rests in between moving positions. Other than her current medications she is not taking any
medications to control her current symptoms of feeling dizzy and fatigue.
PMH:
Dementia
Diabetes
COPD
Anemia
Hypertensive
Depression
Neuropathy
Medications:
Donepezil 5 mg po daily
Fluticasone proprionate and salmeterol 250/50 1 puff bid
Losartan 50 mg po daily
Metoprolol 50 mg po daily
Gabapentin 300 mg tid
Paroxetine 20 mg po daily
Quetiapine 200 mg po bid
Insulin glargine 30 units’ SQ qhs
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Nitrofurantoin ER 100 mg po bid X 7 days (3 days left)
Multivitamin po daily
Iron sulfate 325 mg po bid

Allergies: NKA
Social history:
She does not smoke, no alcohol use or illicit drug use.
Personal and family history:
She resides in an assisted living facility; has a daughter; medications are managed at the assisted
living
REVIEW OF SYSTEM:
Constitution: she denies having fever or chills
HEENT: denies having headache, c/o of dizziness; denies having trouble hearing or with her eye
sight and uses glasses. Denies having nasal drainage or sinus concerns. Denies having dysphagia
Cardiovascular: denies having edema
Respiratory: denies having SOB or dyspnea;
GI: denies having abdominal pain
GU: denies dysuria or frequency; denies nausea or emesis; denies constipation
Musculoskeletal: states that she is independent at the assisted living
Physical Examination:
V/S: BP 88/40; P 50; R 24; T 98.6
FSBS this morning 107
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Constitution: she is alert and oriented x 3; does not appear to be in any acute distress; groomed
appropriately for the season
HEENT: head – atraumatic; eyes – wears glasses; ear – symmetrical with no visible deformity;
nose- no drainage and nares are patent, denies sinus pressure; throat – able to swallow, thyroid
midline.
Cardiovascular: Normal S1 and S2; no edema
Respiratory: Lung sounds are clear with no distress, no wheezing or rales
GI: abdomen is soft and non-tender; positive bowel sounds
GU: CVS negative; denies dysuria or frequency; denies nausea or emesis; denies constipation
Musculoskeletal: observed to be ambulatory
Assessment & Plan
Differential Diagnosis: Drug interaction; Hypotension; Anemia; Bradycardia;
Drug Interaction – currently on various medication with probability of drug interaction. No
clinical indication for some of the medications.
Plan – will review and discontinue one medication at a time with follow up as needed and
review with pharmacist on contraindications. Initial medication to be discontinued will be
Quetiapine/Seroquel on the next visit.
Hypotension – Blood pressure 88/40 with complaints of dizziness; on metoprolol 50 mg daily
with side effects causing dizziness and fatigue.
Plan – Will reduce metoprolol to 25 mg po daily and continue to monitor blood pressure daily,
with nurse visit and report blood pressures lower than 80/40, c/o of dizziness, lightheadedness,
fatigue, diarrhea, confusion.
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Anemia – Currently on iron and multivitamin supplements, has complaints of fatigue that has
been ongoing experience. CBC - WNL; Iron studies – WNL; ferritin - WNL
Plan – will continue with current treatment plan of iron supplements and reassess on fatigue
within 1 week.

A Review of Literature
A literature review was completed in order to assess the incidence, causes, and
management of polypharmacy. The research was done using databases such as PubMed,
CINAHL, Medline, and Cochrane. The keywords included “Polypharmacy in geriatric”,
“Incidence in polypharmacy”, and Management of polypharmacy”. Numerous articles that were
peer reviewed and had the word “Polypharmacy”, were further evaluated for this paper. They
were then narrowed down using the articles summaries or conclusion to help determine their
association with the current topic. Articles that addressed using the keywords “incidences and
management of polypharmacy” were selected and also further reviewed. A total of sixteen
articles were considered relevant and related well with the topic. Those articles reviewed
prevalence and negative effects of polypharmacy, and interventions that could help manage
polypharmacy. Some articles indicated common adverse and drug interactions related to
polypharmacy. A further review of the articles was done to selectively use articles with most
literature on incidence, causes and management of polypharmacy, which narrowed the articles
down to ten.
Incidence and Causes of Polypharmacy
Sganga, et. al. (2015) reports that polypharmacy is related to hospitalization of older
adults and complex disease processes. Reports in the article explain that the use of polypharmacy
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has an increased the rate of adverse reactions. These adverse reactions may lead to
hospitalization. The article states that patients taking at least seven drugs or more have a higher
chance of medication error. Explaining that older adults that have many drugs, at times lack a
good medication management like a pill box and could forget the drugs that they took increasing
a chance of error or doubling the doses.
Marcum, Thorpe, Gellad, & Donohue, (2014) explain that using numerous pharmacies
versus one/similar pharmacy may increase the likelihood of polypharmacy. The authors also
indicate that multi pharmacy was associated with higher medication non adherence, poor
communication with providers, patients and pharmacists. The article explains that when
considering work loads of pharmacists, chances of overrides, lack of a complete medication
history and the multi pharmacy use can also cause incidents such as use of warfarin and antiinflammatories leading to gastrointestinal bleeding. Communication therefore plays an important
role in reducing the incidences of polypharmacy. Field, Gurwitz, Avorn, et. al (2001), the study
was completed on long term care patients that had multiple drugs. The study showed that a
number of the patients had an adverse drug effect at some point in the study that was either life
threatening, serious or fatal. The study concluded that adverse drug effects were preventable,
recommending reducing the number of drugs that were being taken, reviewing indications of use
more often and reducing prescription. Reviewing drugs can be done with a multisystem approach
by using various team members like medical assistants, clinic nurses, providers, pharmacies
among other providers that have the knowledge and understanding of being able to check which
medications patients are taking.
Fried, et. al. (2014), show that polypharmacy was a marker for poor health since most
people that take multiple medications had a number of co-morbidities. The study expected to
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show that polypharmacy was related to fall risks, adverse drug reactions events, hospitalization,
mortality, physical and cognitive impairment. However, the results indicated an independent
relationship between polypharmacy and outcomes for example medications and mortality in
older adults found no mortality benefit.
Management of Polypharmacy
Spinewine, et. al. (2007) explains that since the geriatric population has a wide
heterogeneity with health conditions ranging from fit to frail, it is not appropriate to generalize
their cares or prescribing decisions. They further elaborate that medications being a fundamental
part of their care, providers should use good measures to prescribe medications that are
beneficial to these age groups. The article uses three values to judge for appropriateness which
include, what the patient wants, scientific or technical rationalism which includes the clinical
pharmacology of the drug and the general good. When understanding “what the patient wants”,
provider should listen to patients’ and know what they are experiencing. A cent example is a
patient that came to the clinic with concerns on occasional numbness to their bilateral wrists and
were worried that they could be having a stroke due to their family history. Upon assessment and
review of their system, there were no red flags indicating a stroke. On examination the patient
then stated that they have noticed the numbness when sleeping with their hand under the head.
Often it has been a habit they have developed due to a recent shift change. On days that they
have a day off and nap in their bed, the complaint has not been evident. Most differential
diagnosis were negative and the conclusion was that they must be pinching their nerves when
sleep laying their head on their hands. A change of that habit and follow up within 2 weeks
resolved the concern. O medications were needed in this case and so many other cases that one
may come across in the field. At times patients’ feel better talking with their providers for
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assurance versus medication initiation. Various studies indicate that using geriatric medicine
service approaches, having pharmacist involvement in reviewing contraindications, patient care
and computerized decision support can improve the appropriateness of prescribing in geriatrics.
Sganga, et. al. (2015) explains that using a pill box can help manage medications and
organize the times those medications are taken thereby reducing drug interactions or over dose
related to doubling the doses. Ferner & Aronson, (2006) states that an understanding of
prescription medications by providers and patients can help manage polypharmacy and may
reduce drug incidences. An example is knowing the common side effects of medications and
being able to identify the changes like an increased level of prothrombin time in a patient taking
Coumadin may be related to a drug interaction with a new drug or change. The article concluded
that more research and resources are needed to support providers with appropriate information to
help both providers and patients make informed decisions when prescribing and taking
medications. Marcum, Thorpe, Gellad, & Donohue, (2014) states that pharmacies can manage
and may reduce polypharmacy by using the pharmacy software which can randomly checks for
possible alerts that hence prevent drug interactions from occurring.
Tan, Eastment, Poudel, & Hubbard, (2015) also reaffirms the importance of providers
informing their patients and ensuring that they understanding which medications they have been
prescribed, the risks and benefits of the drug, and their goal of care. When patients are informed,
they can make informed decision to take the medications and hopefully update their providers
when they suspect that they are experiencing side effects. Patients can be able to identify which
medication they recently changed and clue in the providers to take a closer approach on
addressing the concern versus treating a side effect of a medication that could probably be
discontinued and resolve the problem. The center for disease control and prevention (2010)
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explains in an article that the use of new medications can be used to improve one’s quality of
life. However, the article also states that inappropriate prescription can be detrimental to one’s
health thereby as earlier shown in this paper an understanding of medication use should be well
known before prescribing the medications. Providers and patients need to be aware of which
medications they are taking, taking initiatives like reading the paper work provided to patients’
by the pharmacist or having a consult at the pharmacy for all new medications that they are
receiving.
World health organization (2012) concludes with 12 interventions that are relevant
toward managing polypharmacy “ establishing of a multidisciplinary national body to coordinate
policies on medicine use; use of clinical guidelines; development and use of national essential
medicines list; establishment of drug and therapeutic committees in districts and hospitals;
inclusion of problem-based pharmacotherapy training in undergraduate curricula; continuing inservice medical education as a licensure requirement; supervision, audit and feedback; use of
independent information on medicines; public education about medicines; avoidance of perverse
financial incentives; use of appropriate and enforced regulation; sufficient government
expenditure to ensure availability of medicines and staff”. The above steps if implemented
throughout the health systems, incidence and management of polypharmacy can be attained.
Learning Points
•

Communication is a key to managing polypharmacy, when patients and providers
are informed of the potential risks versus the benefits, they will more than likely
use available resources to reduce harm. For instance patients can quickly and
easily identify changes which need to be reported to their providers. Providers
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would also have screening in place to prevent harm like having routine blood
count on patients taking clozapine. With open communication harm can be
detected early and interventions placed to maintain safety.
•

Collaboration with other team members. When patients are seen with providers, a
quick review of the patients’ medications would be relevant. Using resources
available at various clinics and hospitals like the use of pharmacists to evaluate
the clinical need of the medications they are taking and address possible
contraindications. Having clinic nurses’ complete follow up calls to at risk
patients that start new medications to confirm their understanding.

•

Educating patients of expected and unexpected actions on their current
medications. An example providing essential tools like automated blood pressure
cuffs and having patients keep records of their reading. Ensuring that patients’
that are diabetic bring their glucose meters to their primary care provider
appointments for a closer look into their blood glucose readings. Reviewing the
levels with the patients and providing teaching on events that seem unclear or
reinforcing better control of the levels.

•

Being advocates for patients and addressing concerns that are recognized at the
clinic or hospital with appropriate interventions. For instance when a provider
sees a patient that is elderly and is at risk of polypharmacy related to poor
management of her medications. Providers should initiate an in home assessment
for medication management if covered by insurance. Providers can also have
house calls paramedics that visit people at home to help manage their medications
and reduce incidences that can be caused with poor medication management.
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•

Self-efficacy in patients can also attribute to managing polypharmacy. This can be
achieved by patients having the motivation to make it when circumstances change
and not rely on medications to help sort out their problems. Having the ability to
recognize that not all disease processes are treated with antibiotics or pain
medications, being able to pursue non pharmacological interventions like physical
therapy to manage pain.
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